Detail akcie DexCom online

Business Summary: DexCom, Inc. is a medical device company. The Company enables people to take real-time control of health through continuous glucose monitoring (CGM) systems. The Company is engaged in diabetes care technology. Based on the needs of users, caregivers, and providers, the Company works to simplify and improve diabetes management around the world. The Company is primarily focused on the design, development, and commercialization of CGM, systems for the management of diabetes by patients, caregivers, and clinicians around the world. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Dexcom Stelo is designed specifically for people with type II diabetes who do not use insulin and are not at risk for hypoglycemia. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, DexCom Inc revenues increased 24% to $3.62B. Net income increased 59% to $541.5M. Revenues reflect United States segment increase of 23% to $2.63B, Outside of United states segment increase of 30% to $997M. Net income benefited from Income from equity investments increase from $200K to $1.9M (income), Interest on lease liabilities decrease of 3% to $3.2M (expense).